Streetbeat News

NGENF

NervGen Pharma Corp

Industry

Medicinal and Botanical Manufacturing

Open

1.98

Mkt cap

131M

Volume

2.9K

High

1.98

P/E Ratio

-6.93

52-wk high

2.99

Low

1.87

Div yield

N/A

52-wk low

1.20

NervGen Pharma Corp. reported its Q3 2024 financial results, highlighting progress in its clinical trials for NVG-291 and preclinical studies for NVG-300. The company is nearing completion of participant enrollment for its Phase 1b/2a trial in spinal cord injury.

Portfolio Pulse from

November 14, 2024 | 1:45 pm

NervGen Pharma Corp., a clinical-stage biotech company, will present at the Stifel 2024 Healthcare Conference. The company's President & CEO, Mike Kelly, will participate in a fireside chat on November 18, 2024.

Portfolio Pulse from

November 07, 2024 | 1:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.